Hinova688302 Shis An International And Clinical Stage Pharmaceutical Company Focused On Developing New Therapeutics For Cancers And Metabolic Syndromes Through Protac And Deuteration Technologywe Are Committed To The Discovery And Development Of Innovative Drugs With Global Interests That Meet The Significant Clinical Needshinova Pharma Has 4 Core R&D Platformswhich Are Protacproteolysis Targeting Chimeraplatformdeuteration Platformnovel Target Discovery And Validation Platformand Lead Compound Optimization Screening Platformwe Have Submitted More Than 200 Pct And National Patentswith More Than 60 Patents Granted In China And In The Globesuch As The Useuand Japanwe Have 10 Innovative Projects In The R&D Stageand 2 National Major Projects Ofsignificant New Drugs Creationawarded By Ministry Of Science And Technology Of The People S Republic Of Chinathe Company Is Led By A Management Team Comprised Of Accomplished Experts In The Biotechnology And Pharmaceutical Industriesthe Core Team Members Are Mostly From The World S Top 500 Pharmaceutical Companieswith 2 National Level And Several Provincial Level Expertsamong The Pipeline And Programshc 1119 Has Entered The Global Multicenter Phase Iii Clinical Trials For The Treatment Of Castration Resistant Prostate Cancerhp501 For The Treatment Of Hyperuricemia And Goutthe Phase Ii Clinical Trial Of Which Has Been Completed In Chinathe Phase Ii Clinical Trial Of Hp558 Which Is Potenially Effective For Esophageal Cancerhas Been Approved By Nmpahp518An Orally Bioavailable Chimeric Degrader Targeting Aris In Phase I Clinical Trials In Australia
